MicroRNA-34, microRNA-130, microRNA-148, microRNA-181, microRNA-194 and microRNA-605 expression in colon cancer tissue

Purpose of the study. Determination of the expression of microRNA‑34, microRNA‑130, microRNA‑148, microRNA‑181, microRNA‑194 and microRNA‑605 in colon tumor tissue depending on the clinical and morphological features of the tumor and the effectiveness of treatment.

Materials and methods. The study included 56 patients diagnosed with colorectal cancer aged 43 to 75 years with the average age of 54 years. Taking into account the local prevalence of the process patients received surgical or combined treatment, including neoadjuvant chemotherapy, in the clinics of the Cancer Research Institute, Tomsk NRMC. MicroRNA expression was determined by polymerase chain reaction (PCR) in real time.

Results. The obtained information revealed the relation of microRNA‑130 to the tumor size. The development of regional metastases was associated with changes in microRNA‑130, microRNA‑194 and microRNA‑605. The level of histological organization of the tumor was associated with microRNA‑34, microRNA‑130, microRNA‑148, and the response to therapy – with microRNA‑130, microRNA‑148 and microRNA‑605. In addition, according to the study, the significance of microRNA‑130 was revealed, which is associated with tumor spread, histological differentiation and response to antitumor therapy.

Conclusion. The features of expression of microRNA‑34, microRNA‑130, microRNA‑148, microRNA‑181, microRNA‑194 and microRNA‑605 associated with clinical and morphological features of colon tumors were revealed. Correlations between the studied indicators are noted, which probably determine the outcome and prognosis of the disease.

1. Simon K. Colorectal cancer development and advances in screening. Clin Interv Aging. 2016;11:967–976. https://doi.org/10.2147/CIA.S109285

2. Poturnajova M, Furielova T, Balintova S, Schmidtova S, Kucerova L, Matuskova M. Molecular features and gene expression signature of metastatic colorectal cancer (Review). Oncol Rep. 2021 Apr;45(4):10. https://doi.org/10.3892/or.2021.7961

3. Wang B, Shen Z long, Gao Z dong, Zhao G, Wang C you, Yang Y, et al. MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway. Cell Cycle. 2015;14(7):1046–1058. https://doi.org/10.1080/15384101.2015.1007767

4. Rokavec M, Öner MG, Li H, Jackstadt R, Jiang L, Lodygin D, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014 Apr;124(4):1853–1867. https://doi.org/10.1172/jci73531

5. Li Y, Jin L, Rong W, Meng F, Wang X, Wang S, et al. Expression and significance of miR-34 with PI3K, AKT and mTOR proteins in colorectal adenocarcinoma tissues. Cell Mol Biol (Noisy-le-grand). 2022 Sep 30;68(9):57–62. https://doi.org/10.14715/cmb/2022.68.9.9

6. Miao C, Zhang J, Zhao K, Liang C, Xu A, Zhu J, et al. The significance of microRNA-148/152 family as a prognostic factor in multiple human malignancies: a meta-analysis. Oncotarget. 2017 Jun 27;8(26):43344–43355. https://doi.org/10.18632/oncotarget.17949

7. Mei H, Wen Y. MicroRNAs for Diagnosis and Treatment of Colorectal Cancer. Endocr Metab Immune Disord Drug Targets. 2021;21(1):47–55. https://doi.org/10.2174/1871530320999200818134339

8. Sukocheva OA, Liu J, Neganova ME, Beeraka NM, Aleksandrova YR, Manogaran P, et al. Perspectives of using microRNA-loaded nanocarriers for epigenetic reprogramming of drug resistant colorectal cancers. Semin Cancer Biol. 2022 Nov;86(Pt 2):358–375. https://doi.org/10.1016/j.semcancer.2022.05.012

9. Spirina LV, Tarasova AS, Dobrodeev AYu, Kostromitskii DN, Avgustinovich AV, Afanas’ev SG, et al. Molecular markers of colorectal cancer, association with objective tumor response to treatment. Problems in Oncology. 2022;68(1):85–90. (In Russ.). https://doi.org/10.37469/0507-3758-2022-68-1-85-90, EDN: STKSOQ

10. Li J, Tian F, Li D, Chen J, Jiang P, Zheng S, et al. MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression. FEBS Lett. 2014 Sep 17;588(18):3491–3500. https://doi.org/10.1016/j.febslet.2014.08.008

11. Peng Z, Duan F, Yin J, Feng Y, Yang Z, Shang J. Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test. J Transl Med. 2019 Oct 22;17(1):347. https://doi.org/10.1186/s12967-019-2093-y

12. Zhang J, Zhang K, Bi M, Jiao X, Zhang D, Dong Q. Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anticancer Drugs. 2014 Mar;25(3):346–352. https://doi.org/10.1097/cad.0000000000000049

13. Rezaei T, Amini M, Hashemi ZS, Mansoori B, Rezaei S, Karami H, et al. microRNA-181 serves as a dual-role regulator in the development of human cancers. Free Radic Biol Med. 2020 May 20;152:432–454. https://doi.org/10.1016/j.freeradbiomed.2019.12.043

14. Chang HY, Ye SP, Pan SL, Kuo TT, Liu BC, Chen YL, et al. Overexpression of miR-194 Reverses HMGA2-driven Signatures in Colorectal Cancer. Theranostics. 2017;7(16):3889–3900. https://doi.org/10.7150/thno.20041

15. Tang K, Wu Z, Sun M, Huang X, Sun J, Shi J, et al. Elevated MMP10/13 mediated barrier disruption and NF-κB activation aggravate colitis and colon tumorigenesis in both individual or full miR-148/152 family knockout mice. Cancer Lett. 2022 Mar 31;529:53–69. https://doi.org/10.1016/j.canlet.2021.12.033

16. Pichler M, Winter E, Ress AL, Bauernhofer T, Gerger A, Kiesslich T, et al. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. J Clin Pathol. 2014 Mar;67(3):198–203. https://doi.org/10.1136/jclinpath-2013-201904

17. Yang X, Sun Y, Zhang Y, Han S. Downregulation of miR 181b inhibits human colon cancer cell proliferation by targeting CYLD and inhibiting the NF κB signaling pathway. Int J Mol Med. 2020 Nov;46(5):1755–1764. https://doi.org/10.3892/ijmm.2020.4720

18. Liu T, Fang Y. MiR-194-3p modulates the progression of colorectal cancer by targeting KLK10. Histol Histopathol. 2022 Mar;37(3):301–309. https://doi.org/10.14670/hh-18-413

19. Zhao J, Wang Y, Wang Y, Gao J, Wu X, Li H. miR-194-3p represses the docetaxel resistance in colon cancer by targeting KLK10. Pathol Res Pract. 2022 Aug;236:153962. https://doi.org/10.1016/j.prp.2022.153962

20. Sahu SS, Dey S, Nabinger SC, Jiang G, Bates A, Tanaka H, et al. The Role and Therapeutic Potential of miRNAs in Colorectal Liver Metastasis. Sci Rep. 2019 Nov 1;9(1):15803. https://doi.org/10.1038/s41598-019-52225-2

21. Spirina LV, Avgustinovich AV, Afanas’ev SG, Cheremisina OV, Volkov MY, Choynzonov EL, et al. Molecular Mechanism of Resistance to Chemotherapy in Gastric Cancers, the Role of Autophagy. Curr Drug Targets. 2020;21(7):713–721. https://doi.org/10.2174/1389450120666191127113854

22. Zhang G, Wu YJ, Yan F. MicroRNA-130-5p promotes invasion as well as migration of lung adenocarcinoma cells by targeting the EZH2 signaling pathway. Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9480–9488. https://doi.org/10.26355/eurrev_201911_19442